Immunotherapy duo before liver surgery shows promise against cancer

NCT ID NCT03682276

Completed Disease control Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This trial investigates whether giving two immunotherapy drugs, ipilimumab and nivolumab, before liver surgery can help shrink tumors in people with liver cancer (hepatocellular carcinoma). Participants receive the drugs in the weeks leading up to their planned surgery. The study focuses on safety and whether the treatment delays surgery or causes side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ipilimumab and Nivolumab (immunotherapies)
What this could lead to: If successful, this approach could shrink liver tumors before surgery, potentially improving long-term outcomes for patients with hepatocellular carcinoma.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply broadly. Immunotherapies can cause serious side effects, including immune system overactivation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Imperial College Healthcare NHS Trust

London, Greater London, W12 0HS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.